Literature DB >> 34118479

Impact of inappropriate empirical antibiotic treatment on clinical outcomes of urinary tract infections caused by Escherichia coli: a retrospective cohort study.

Hongying Zhu1, Yanhui Chen1, Yaping Hang1, Hong Luo1, Xueyao Fang1, Yanping Xiao1, Xingwei Cao1, Shan Zou1, Xiaoyan Hu1, Longhua Hu1, Qiaoshi Zhong2.   

Abstract

OBJECTIVES: We aimed to determine the clinical impact of inappropriate empirical antibiotic treatment (IEAT) compared with appropriate empirical antibiotic treatment (AEAT) in hospitalised patients with urinary tract infections (UTIs) caused by Escherichia coli (E. coli).
METHODS: This retrospective cohort study included adult patients with a primary diagnosis of UTI who were treated with empirical antibiotics at a tertiary hospital in southern China over a 2-year period. Clinical data of patients who received IEAT were compared with those of patients receiving AEAT. We used multivariable logistic regression to identify the predictors for receiving IEAT and the risk factors affecting clinical outcomes.
RESULTS: A total of 213 patients were enrolled (median age, 61 years), of whom 103 (48.4%) received IEAT. IEAT was associated with empirical use of fluoroquinolones, male sex and age-adjusted Charlson comorbidity index (aCCI) score >6. Hospital length of stay (LOS) was longer for patients who received IEAT than for those who received AEAT (13.6 ± 8.6 days vs. 10.8 ± 7.9 days; P = 0.008). IEAT was an independent risk factor for longer LOS along with aCCI score ≥2, lung disease and cardiac disease.
CONCLUSION: Empirical use of fluoroquinolones for UTIs should be avoided, especially in male patients with aCCI score >6. Improved empirical antimicrobial therapy may have a beneficial impact in reducing bacterial resistance and healthcare costs by decreasing the LOS. Therefore, interventions to promote in-depth antibiotic stewardship programmes in China are needed.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Escherichia coli; Fluoroquinolones; Inappropriate empirical antibiotic treatment; Urinary tract infection

Year:  2021        PMID: 34118479     DOI: 10.1016/j.jgar.2021.05.016

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  6 in total

1.  The Appropriateness of Empiric Treatment of Urinary Tract Infections in a Tertiary Teaching Hospital in Joran: A Cross-Sectional Study.

Authors:  Rama Alkhawaldeh; Rana Abu Farha; Khawla Abu Hammour; Eman Alefishat
Journal:  Antibiotics (Basel)       Date:  2022-05-06

Review 2.  Aeromonas and Human Health Disorders: Clinical Approaches.

Authors:  Rafael Bastos Gonçalves Pessoa; Weslley Felix de Oliveira; Maria Tereza Dos Santos Correia; Adriana Fontes; Luana Cassandra Breitenbach Barroso Coelho
Journal:  Front Microbiol       Date:  2022-05-31       Impact factor: 6.064

3.  High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020.

Authors:  Jonas Salm; Florian Salm; Patricia Arendarski; Tobias Siegfried Kramer
Journal:  Euro Surveill       Date:  2022-07

Review 4.  Adherence to European Association of Urology Guidelines and State of the Art of Glycosaminoglycan Therapy for the Management of Urinary Tract Infections: A Narrative Review and Expert Meeting Report.

Authors:  Gernot Bonkat; Tommaso Cai; Carlotta Galeone; Bela Koves; Franck Bruyere
Journal:  Eur Urol Open Sci       Date:  2022-08-23

5.  Compliance to Guidelines in Prescribing Empirical Antibiotics for Individuals with Uncomplicated Urinary Tract Infection in a Primary Health Facility of Ghana, 2019-2021.

Authors:  Helena Owusu; Pruthu Thekkur; Jacklyne Ashubwe-Jalemba; George Kwesi Hedidor; Oksana Corquaye; Asiwome Aggor; Allen Steele-Dadzie; Daniel Ankrah
Journal:  Int J Environ Res Public Health       Date:  2022-09-29       Impact factor: 4.614

6.  Relationship between the appropriateness of antibiotic treatment and clinical outcomes/medical costs of patients with community-acquired acute pyelonephritis: a multicenter prospective cohort study.

Authors:  Choseok Yoon; Se Yoon Park; Bongyoung Kim; Ki Tae Kwon; Seong-Yeol Ryu; Seong-Heon Wie; Hyun-Uk Jo; Jieun Kim; Kyung-Wook Hong; Hye In Kim; Hyun Ah Kim; Mi-Hee Kim; Mi-Hyun Bae; Yong-Hak Sohn; Jieun Kim; Yangsoon Lee; Hyunjoo Pai
Journal:  BMC Infect Dis       Date:  2022-02-01       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.